Low-dose prostaglandin E2 analogue for cervical dilatation prior to pregnancy termination

Abstract

The trauma of mechanical cervical dilatation preceding abortion is directly related to the degree of cervical resistance. Prostaglandins may reduce cervical rigidity but are accompanied by undesirable side effects. Our aims were to ascertain if a low-dose (10 mg) analogue (9-deoxo-16, 16 dimethyl-9-methylene PGE2) is effective and well tolerated and, if so, to try to determine the possible mechanism by which it works. To this end, we studied 39 women with gestational ages ranging from 7 to 19 weeks who were given a single vaginal suppository 1 to 4 hours before suction curettage. In addition to demographic data on age, gravidity, parity, and previous abortions, we determined progesterone, human chorionic gonadotropin and prostaglandin plasma levels. This low-dose prostaglandin E2 analogue was found to be effective in achieving cervical dilatation and softening with minimal side effects (mild nausea in one patient only). Mean cervical dilatation achieved was 7.8 +/- 2.3 mm. Softening was apparent and facilitated additional instrumental dilatation when required. No correlation was found between drug effectiveness and gravidity, gestational age, or duration of action. There was no detectable trend with regard to baseline progesterone or human chorionic gonadotropin levels. This suggested a specific sensitivity to the local effect by the drug, apparently unrelated to dosage.

PIP: The trauma of mechanical cervical dilatation preceding abortion is directly related to the degree of cervical resistance. Prostaglandins (PGs) may reduce cervical regidity but are accompanied by undesirable side effects. The aims of this study were to ascertain if a low dose (10 mg) analogue (9-deoxo-16,16 dimethyl-9-methylene PGE2) is effective and well tolerated and, if so, to try to determine the possible mechanism by which it works. To this end, there were 39 women studied withgestational ages ranging from 7-19 weeks who were given a single vaginal suppository 1-4 hours before suction curettage. In addition to demographic data on age, gravidity, parity, and previous abortion, the authors determined progesterone, human chorionic gonadotropin (hCG) and PG plasma levels. This low dose PGE2 analogue was found to be effective in achieving cervical dilatation and softening with minimal side effects (mild nausea in only 1 patient). Mean cervical dilatation was achieved 7.8 +or- 2.3 mm. Softening was apparent and facilitated additional instrumental dilatation when required. No correlation was found between drug effectiveness and gravidity, gestational age, or duration of action. There was no detectable trend with regard to baseline progesterone or hCG. This suggested a specific sensitivity to the local effect by the drug, apparently unrelated to dosage.